Triple Drug Therapy for Advanced Bladder Cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a combination of three drugs (enfortumab vedotin, pembrolizumab, and quemliclustat) for people with bladder or upper urinary tract cancer that has spread or cannot be removed by surgery. It aims to see if this combination can shrink tumors and help patients live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and have bladder cancer or cancer of the renal pelvis or ureter that is advanced or has spread.
- You must not have had any prior treatment for advanced cancer (except certain surgeries or radiation).
- You must have a tumor sample available or be willing to have a biopsy.
- You must be able to perform daily activities with little to no help (ECOG score 0-2).
- Your blood counts and organ function (kidney, liver) must be within safe ranges.
- You cannot have certain types of cancer (like small cell or neuroendocrine) or active autoimmune disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two drugs, enfortumab vedotin and pembrolizumab, given before surgery to remove the bladder or ureter in people with advanced bladder or upper urinary tract cancer that has spread to lymph nodes or other organs. The goal is to see if this treatment helps shrink the cancer and improves outcomes.
This trial studies enfortumab vedotin plus pembrolizumab (immunotherapy) for people with advanced bladder cancer that has a “variant” or non-urothelial subtype. It aims to shrink tumors and improve outcomes when standard options have not worked or are no longer enough.
This Phase 2 study tests whether nivolumab and ipilimumab (immunotherapy drugs) plus cabozantinib (a targeted anti-cancer drug) can shrink or control rare cancers of the urinary/reproductive system that have spread. It may help by boosting the immune system and blocking cancer growth signals at the same time.
This trial tests a two-drug combination (pembrolizumab and enfortumab vedotin) followed by maintenance pembrolizumab for people with advanced bladder cancer that has not been treated before. The goal is to see if this approach helps control the cancer for longer.
This trial tests a procedure called therapeutic plasma exchange (TPE) combined with the drugs enfortumab vedotin and pembrolizumab for people with advanced bladder cancer that has stopped responding to standard treatments. The goal is to see if TPE helps the drugs work better.
This trial tests a new drug, CA-4948, combined with pembrolizumab (Keytruda) for people with advanced bladder cancer that grew after prior immunotherapy. The goal is to see if this combination can help when standard treatments stop working.
Hear when a new Stage IV Bladder Cancer AJCC v8 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.